FIELD: medicine.
SUBSTANCE: the present innovation deals with treating Alzheimer's disease due to introducing the antagonist of luteinizing hormone-releasing hormone (LHRH) at the dosages to provide submaximal decrease of follicle-stimulating and luteinizing hormones level up to their normal levels that correspond to those of sex hormones being above their castration level. The innovation provides the desired results of therapy without such unfavorable side effects as the blockade of sex hormones.
EFFECT: higher efficiency of therapy.
12 cl, 1 ex
